JP2005519059A5 - - Google Patents

Download PDF

Info

Publication number: JP2005519059A5
Authority: JP; Japan
Prior art keywords: gly; ala; glu; arg; glp
Prior art date: 2003-01-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2003557592A

Other languages

English (en)

Japanese (ja)

Other versions

JP4733922B2 (ja

JP2005519059A (ja

Filing date

2003-01-10

Publication date

2006-03-02

2002-01-10 Priority claimed from GBGB0200507.2A external-priority patent/GB0200507D0/en

2002-09-24 Priority claimed from PCT/US2002/031944 external-priority patent/WO2003026591A2/en

2003-01-10 Application filed filed Critical

2003-01-10 Priority claimed from PCT/GB2003/000062 external-priority patent/WO2003057235A2/en

2005-06-30 Publication of JP2005519059A publication Critical patent/JP2005519059A/ja

2006-03-02 Publication of JP2005519059A5 publication Critical patent/JP2005519059A5/ja

2011-07-27 Application granted granted Critical

2011-07-27 Publication of JP4733922B2 publication Critical patent/JP4733922B2/ja

2023-01-10 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 6
MFMDKJIPHSWSBM-GUBZILKMSA-N Ala-Lys-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O MFMDKJIPHSWSBM-GUBZILKMSA-N 0.000 description 4
CCQOOWAONKGYKQ-BYPYZUCNSA-N Gly-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)CN CCQOOWAONKGYKQ-BYPYZUCNSA-N 0.000 description 4
LLWQVJNHMYBLLK-CDMKHQONSA-N Gly-Thr-Phe Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LLWQVJNHMYBLLK-CDMKHQONSA-N 0.000 description 4
AFPFGFUGETYOSY-HGNGGELXSA-N His-Ala-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AFPFGFUGETYOSY-HGNGGELXSA-N 0.000 description 4
GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 4
WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 4
VZFPYFRVHMSSNA-JURCDPSOSA-N Phe-Ile-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC1=CC=CC=C1 VZFPYFRVHMSSNA-JURCDPSOSA-N 0.000 description 4
IVDFVBVIVLJJHR-LKXGYXEUSA-N Thr-Ser-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O IVDFVBVIVLJJHR-LKXGYXEUSA-N 0.000 description 4
WMBFONUKQXGLMU-WDSOQIARSA-N Trp-Leu-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N WMBFONUKQXGLMU-WDSOQIARSA-N 0.000 description 4
KSCVLGXNQXKUAR-JYJNAYRXSA-N Tyr-Leu-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O KSCVLGXNQXKUAR-JYJNAYRXSA-N 0.000 description 4
PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 4
108010006664 gamma-glutamyl-glycyl-glycine Proteins 0.000 description 4
108010073969 valyllysine Proteins 0.000 description 4
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 3
RXVOMIADLXPJGW-GUBZILKMSA-N His-Asp-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O RXVOMIADLXPJGW-GUBZILKMSA-N 0.000 description 2
HOYQLNNGMHXZDW-KKUMJFAQSA-N Phe-Glu-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O HOYQLNNGMHXZDW-KKUMJFAQSA-N 0.000 description 2
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 description 1
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
UKVFVQPAANCXIL-FJVFSOETSA-N glp-1 (1-37) amide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 UKVFVQPAANCXIL-FJVFSOETSA-N 0.000 description 1
108010063245 glucagon-like peptide 1 (7-36)amide Proteins 0.000 description 1
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1

JP2003557592A 2002-01-10 2003-01-10 摂食行動の修正 Expired - Fee Related JP4733922B2 (ja)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
GB0200507.2		2002-01-10
GBGB0200507.2A GB0200507D0 (en)	2002-01-10	2002-01-10	Appetite suppression
US39210902P	2002-06-28	2002-06-28
US60/392,109		2002-06-28
PCT/US2002/031944 WO2003026591A2 (en)	2001-09-24	2002-09-24	Modification of feeding behavior
USPCT/US02/31944		2002-09-24
PCT/GB2003/000062 WO2003057235A2 (en)	2002-01-10	2003-01-10	Modification of feeding behavior

Related Child Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2009193064A Division JP5226628B2 (ja)	2002-01-10	2009-08-24	摂食行動の修正
JP2010275256A Division JP2011052018A (ja)	2002-01-10	2010-12-10	摂食行動の修正

Publications (3)

Publication Number	Publication Date
JP2005519059A JP2005519059A (ja)	2005-06-30
JP2005519059A5 true JP2005519059A5 (2)	2006-03-02
JP4733922B2 JP4733922B2 (ja)	2011-07-27

Family

ID=32992571

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
JP2003557592A Expired - Fee Related JP4733922B2 (ja)	2002-01-10	2003-01-10	摂食行動の修正
JP2009193064A Expired - Fee Related JP5226628B2 (ja)	2002-01-10	2009-08-24	摂食行動の修正
JP2010275256A Pending JP2011052018A (ja)	2002-01-10	2010-12-10	摂食行動の修正

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
JP2009193064A Expired - Fee Related JP5226628B2 (ja)	2002-01-10	2009-08-24	摂食行動の修正
JP2010275256A Pending JP2011052018A (ja)	2002-01-10	2010-12-10	摂食行動の修正

Country Status (5)

Country	Link
EP (2)	EP1474163A2 (2)
JP (3)	JP4733922B2 (2)
AU (2)	AU2003201998C1 (2)
CA (1)	CA2472882A1 (2)
WO (1)	WO2003057235A2 (2)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7048906B2 (en)	1995-05-17	2006-05-23	Cedars-Sinai Medical Center	Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US20050272652A1 (en)	1999-03-29	2005-12-08	Gault Victor A	Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
EP2123293A3 (en)	2000-12-14	2010-09-08	Amylin Pharmaceuticals, Inc.	Peptide YY and petide YY agonists for treatment of metabolic disorders
GB0121709D0 (en)	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
CN100350968C (zh)	2001-09-24	2007-11-28	皇家创新有限公司	饮食行为的改进
US9321832B2 (en)	2002-06-28	2016-04-26	Domantis Limited	Ligand
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
BR0316685A (pt)	2002-12-17	2005-11-01	Nastech Pharm Co	Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade
US7229966B2 (en)	2002-12-17	2007-06-12	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7186692B2 (en)	2002-12-17	2007-03-06	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US20070027073A1 (en) *	2003-04-08	2007-02-01	Menachem Rubinstein	Long-acting derivatives of pyy agonists
WO2005053726A1 (en) *	2003-11-25	2005-06-16	Bayer Pharmaceuticals Corporation	Selective neuropeptide y2 receptor agonists
EP2298337B1 (en)	2003-12-09	2017-02-22	Novo Nordisk A/S	Regulation of food preference using GLP-1 agonists
US8076288B2 (en)	2004-02-11	2011-12-13	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides having glucose lowering activity
NZ579621A (en)	2004-02-11	2011-03-31	Amylin Pharmaceuticals Inc	Hybrid polypeptides with selectable properties
US8603969B2 (en)	2004-02-11	2013-12-10	Amylin Pharmaceuticals, Llc	Pancreatic polypeptide family motifs and polypeptides comprising the same
WO2005090388A1 (en)	2004-03-19	2005-09-29	The University Of Queensland	Alpha helical mimics, their uses and methods for their production
US20080254450A1 (en) *	2004-03-24	2008-10-16	Anne Philippi	Human Obesity Susceptibility Genes Encoding Peptide Hormones and Uses Thereof
WO2005110457A2 (en) *	2004-05-18	2005-11-24	Aditech Pharma Ab	Treatment of eating disorders and induction of lipolysis
EP1758575A1 (en) *	2004-06-11	2007-03-07	Novo Nordisk A/S	Counteracting drug-induced obesity using glp-1 agonists
CA2580991A1 (en)	2004-10-08	2006-04-20	Amylin Pharmaceuticals, Inc.	Amylin family polypeptide-6 (afp-6) analogs and methods of making and using them
CN101094689B (zh) *	2004-11-01	2013-06-12	安米林药品有限责任公司	治疗肥胖以及肥胖相关疾病和病症的方法
WO2007055728A1 (en) *	2005-11-01	2007-05-18	Amylin Pharmaceuticals, Inc.	Treatment of obesity and related disorders
US8394765B2 (en)	2004-11-01	2013-03-12	Amylin Pharmaceuticals Llc	Methods of treating obesity with two different anti-obesity agents
CN101128487B (zh)	2004-12-02	2012-10-10	杜门蒂斯有限公司	靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
EP2360180A3 (en) *	2004-12-13	2012-02-08	Amylin Pharmaceuticals Inc.	Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
EP1843746B1 (en)	2005-01-14	2011-03-16	Camurus Ab	Somatostatin analogue formulations
US9649382B2 (en)	2005-01-14	2017-05-16	Camurus Ab	Topical bioadhesive formulations
US9757461B2 (en)	2005-01-14	2017-09-12	Camurus Ab	GnRH analogue formulations
KR101245022B1 (ko)	2005-01-21	2013-03-19	카무러스 에이비	약제학적 지질 조성물
WO2007022123A2 (en)	2005-08-11	2007-02-22	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides with selectable properties
KR20070115947A (ko)	2005-02-11	2007-12-06	아밀린 파마슈티칼스, 인크.	선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
US8263545B2 (en)	2005-02-11	2012-09-11	Amylin Pharmaceuticals, Inc.	GIP analog and hybrid polypeptides with selectable properties
GB0504857D0 (en) *	2005-03-09	2005-04-13	Imp College Innovations Ltd	Novel compounds and their effects on feeding behaviour
EP1888031B1 (en)	2005-06-06	2013-01-23	Camurus Ab	Glp-1 analogue formulations
EP2330125A3 (en)	2005-08-11	2012-12-12	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides with selectable properties
EP1940842B1 (en)	2005-09-29	2012-05-30	Merck Sharp & Dohme Corp.	Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
JP2009512715A (ja)	2005-10-21	2009-03-26	ノバルティスアクチエンゲゼルシャフト	レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
WO2007055743A2 (en) *	2005-11-01	2007-05-18	Amylin Pharmaceuticals, Inc.	Treatment of obesity and related disorders
EP2540725A1 (de)	2006-05-04	2013-01-02	Boehringer Ingelheim International GmbH	Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
US8497240B2 (en)	2006-08-17	2013-07-30	Amylin Pharmaceuticals, Llc	DPP-IV resistant GIP hybrid polypeptides with selectable properties
US8173629B2 (en)	2006-09-22	2012-05-08	Merck Sharp & Dohme Corp.	Method of treatment using fatty acid synthesis inhibitors
TWI428346B (zh)	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
JP5319518B2 (ja)	2007-04-02	2013-10-16	Ｍｓｄ株式会社	インドールジオン誘導体
MX354786B (es)	2007-06-04	2018-03-21	Synergy Pharmaceuticals Inc	Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
GB0711656D0 (en)	2007-06-15	2007-07-25	Camurus Ab	Formulations
GB0716385D0 (en)	2007-08-22	2007-10-03	Camurus Ab	Formulations
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
ES2522968T3 (es)	2008-06-04	2014-11-19	Synergy Pharmaceuticals Inc.	Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en)	2008-07-16	2015-02-19	Bausch Health Ireland Limited	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
BRPI0916997A2 (pt)	2008-08-06	2020-12-15	Boehringer Ingelheim International Gmbh	Inibidor de dpp-4 e seu uso
GB0815435D0 (en)	2008-08-22	2008-10-01	Camurus Ab	Formulations
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US20110294735A1 (en) *	2008-11-05	2011-12-01	Merck Sharp & Dohme Corp.	Mechanism of neuromedin u action and uses thereof
WO2010096052A1 (en) *	2009-02-19	2010-08-26	Merck Sharp & Dohme Corp.	Oxyntomodulin analogs
WO2010122090A1 (en) *	2009-04-24	2010-10-28	Glaxo Group Limited	Fgfr1c antibody combinations
KR20240090632A (ko)	2009-11-27	2024-06-21	베링거 인겔하임 인터내셔날 게엠베하	리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
EP2569327B1 (en)	2010-04-27	2016-05-25	Agency For Science, Technology And Research	Eif4e binding peptides
CN102946875A (zh)	2010-05-05	2013-02-27	贝林格尔.英格海姆国际有限公司	组合疗法
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
MX2013004364A (es)	2010-10-19	2013-07-02	Elcelyx Therapeutics Inc	Terapias a base de ligando del receptor quimiosensorial.
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
GB201101459D0 (en)	2011-01-27	2011-03-16	Imp Innovations Ltd	Novel compounds and thier effects on fedding behaviour
WO2013004983A1 (en)	2011-07-04	2013-01-10	Imperial Innovations Limited	Novel compounds and their effects on feeding behaviour
US20130172244A1 (en) *	2011-12-29	2013-07-04	Thomas Klein	Subcutaneous therapeutic use of dpp-4 inhibitor
JP6224084B2 (ja)	2012-05-14	2017-11-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
BR112014029425A2 (pt)	2012-05-25	2017-06-27	Camurus Ab	pré-formulação, dispositivo de administração pré-cheio, kit, processo para a formação de uma pré-formulação, usos de mistura e de um solvente polar, e, método para o tratamento de um sujeito
AR092873A1 (es)	2012-09-26	2015-05-06	Cadila Healthcare Ltd	Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
AU2014235209B2 (en)	2013-03-15	2018-06-14	Bausch Health Ireland Limited	Guanylate cyclase receptor agonists combined with other drugs
AU2014235215A1 (en)	2013-03-15	2015-10-01	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
BR112015030326A2 (pt)	2013-06-05	2017-08-29	Synergy Pharmaceuticals Inc	Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
KR102431436B1 (ko)	2014-08-29	2022-08-10	테스 파마 에스.알.엘.	α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
CN109310697A (zh)	2016-06-10	2019-02-05	勃林格殷格翰国际有限公司	利格列汀和二甲双胍的组合
WO2018069532A1 (en)	2016-10-14	2018-04-19	Tes Pharma S.R.L.	Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018213468A1 (en)	2017-05-16	2018-11-22	The University Of Chicago	Compositions and methods for treating and/or preventing pathogenic fungal infection and for maintenance of microbiome commensalism
WO2019147650A1 (en) *	2018-01-23	2019-08-01	Gila Therapeutics, Inc.	Peptide yy pharmaceutical formulations, compositions, and methods
TW202535916A (zh) *	2018-11-01	2025-09-16	美商美國禮來大藥廠	蛋白質酪胺酸-酪胺酸類似物及其使用方法
AR117122A1 (es)	2018-11-20	2021-07-14	Tes Pharma S R L	INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
JP2024527578A (ja) *	2021-07-08	2024-07-25	ギラセラピューティクスインコーポレイテッド	神経受容体を活性化するための組成物及び方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4002531A (en)	1976-01-22	1977-01-11	Pierce Chemical Company	Modifying enzymes with polyethylene glycol and product produced thereby
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en)	1980-11-10	1985-05-02	Gersonde Klaus	Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja)	1982-01-06	1983-07-13	Nec Corp	デ−タ処理装置
DE3374837D1 (en)	1982-02-17	1988-01-21	Ciba Geigy Ag	Lipids in the aqueous phase
DE3218121A1 (de)	1982-05-14	1983-11-17	Leskovar, Peter, Dr.-Ing., 8000 München	Arzneimittel zur tumorbehandlung
EP0102324A3 (de)	1982-07-29	1984-11-07	Ciba-Geigy Ag	Lipide und Tenside in wässriger Phase
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3483949D1 (de)	1983-09-26	1991-02-21	Udo Dr Med Ehrenfeld	Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
DE3474511D1 (en)	1983-11-01	1988-11-17	Terumo Corp	Pharmaceutical composition containing urokinase
CA1257199A (en)	1986-05-20	1989-07-11	Paul Y. Wang	Preparation containing bioactive macromolecular substance for multi-months release in vivo
JP2887325B2 (ja)	1988-06-28	1999-04-26	ラホヤキャンサーリサーチファウンデーション	デコリンによる細胞増殖の抑制
US5026685A (en)	1988-07-15	1991-06-25	The Salk Institute For Biological Studies	NPY peptide analogs
US5349052A (en)	1988-10-20	1994-09-20	Royal Free Hospital School Of Medicine	Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
WO1990006952A1 (fr)	1988-12-22	1990-06-28	Kirin-Amgen, Inc.	Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5324844A (en)	1989-04-19	1994-06-28	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en)	1989-04-19	1992-06-16	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
SE9002278L (sv)	1990-06-28	1991-12-29	Perstorp Ab	Anvaendning av inositoltrisfosfat foer framstaellning av ett laekemedel
IT1243390B (it)	1990-11-22	1994-06-10	Vectorpharma Int	Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
DE69229283T2 (de)	1991-11-06	1999-09-23	Garvan Institute Of Medical Research, Darlinghurst	Humaner neuropeptid y-y1 rezeptor
DK39892D0 (da)	1992-03-25	1992-03-25	Bernard Thorens	Peptid
KR960701653A (ko)	1993-03-29	1996-03-28	발라수브라마니암 엠비카이파칸	펩타이드 yy의 유사체 및 그의 용도
AU7113594A (en)	1993-06-21	1995-01-17	Enzon, Inc.	Site specific synthesis of conjugated peptides
GB9317618D0 (en)	1993-08-24	1993-10-06	Royal Free Hosp School Med	Polymer modifications
US5965566A (en)	1993-10-20	1999-10-12	Enzon, Inc.	High molecular weight polymer-based prodrugs
US5880131A (en)	1993-10-20	1999-03-09	Enzon, Inc.	High molecular weight polymer-based prodrugs
US5643575A (en)	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5696093A (en)	1994-10-28	1997-12-09	Crc For Biopharmaceutical Research Pty Limited	Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides
US5574010A (en)	1994-11-14	1996-11-12	The Regents Of The University Of California	Treatment of pancreatic tumors with peptide YY and analogs thereof
US5907030A (en)	1995-01-25	1999-05-25	University Of Southern California	Method and compositions for lipidization of hydrophilic molecules
US6558708B1 (en)	1995-05-17	2003-05-06	Cedars-Sinai Medical Center	Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
NZ331186A (en)	1996-02-02	2000-04-28	Alza Corp	Osmotically driven sustained delivery drug delivery capsule
US5962270A (en)	1996-02-06	1999-10-05	Bionebraska, Inc.	Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
US6355478B1 (en)	1996-06-17	2002-03-12	Eli Lilly And Company	Rhesus monkey neuropeptide Y Y2 receptor
IL128332A0 (en) *	1996-08-30	2000-01-31	Novo Nordisk As	GLP-1 derivatives
UA65549C2 (uk) *	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
DE122007000044I2 (de) *	1997-01-07	2011-05-05	Amylin Pharmaceuticals Inc	Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
WO1998032466A1 (en)	1997-01-29	1998-07-30	Polymasc Pharmaceuticals Plc	Pegylation process
US6093692A (en)	1997-09-25	2000-07-25	The University Of Southern California	Method and compositions for lipidization of hydrophilic molecules
US6306819B1 (en) *	1997-10-31	2001-10-23	Massachusetts Institute Of Technology	Method for regulating size of vascularized normal tissue
EP0920864A1 (en) *	1997-12-03	1999-06-09	Pfizer Products Inc.	Combination therapy including a specific beta-3 agonist and an anorectic agent
FR2774674B1 (fr)	1998-02-10	2000-03-24	Atochem Elf Sa	Procede de preparation d'une solution aqueuse de peroxyde d'hydrogene directement a partir d'hydrogene et d'oxygene et dispositif permettant sa mise en oeuvre
JP2002506792A (ja)	1998-02-27	2002-03-05	ノボノルディスクアクティーゼルスカブ	Ｎ末端修飾ｇｌｐ−１誘導体
US6046167A (en)	1998-03-25	2000-04-04	University Of Cincinnati	Peptide YY analogs
FR2777283B1 (fr)	1998-04-10	2000-11-24	Adir	Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5993414A (en)	1998-04-23	1999-11-30	Medtronic, Inc.	Implantable device
TWI242000B (en)	1998-12-10	2005-10-21	Univ Southern California	Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use
WO2000042026A1 (en)	1999-01-15	2000-07-20	Novo Nordisk A/S	Non-peptide glp-1 agonists
US7396809B1 (en) *	1999-02-10	2008-07-08	Curis, Inc.	Methods and reagents for treating glucose metabolic disorders
CA2369549A1 (en)	1999-04-02	2000-10-12	Robert W. Desimone	Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
EP1849475A1 (en)	1999-06-21	2007-10-31	Eli Lilly & Company	Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependent diabetes
EP1076066A1 (en)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
US6608098B1 (en)	1999-08-25	2003-08-19	Banyu Pharmaceutical Co., Ltd.	Isoindole derivatives
AU6798000A (en)	1999-08-26	2001-03-19	Viropharma Incorporated	Compounds, compositions and methods for treating influenza
AU1269501A (en)	1999-11-12	2001-05-30	Novo Nordisk A/S	Use of glp-1 agonists for the inhibition of beta cell degeneration
US6436091B1 (en)	1999-11-16	2002-08-20	Microsolutions, Inc.	Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
WO2001051078A1 (en) *	2000-01-10	2001-07-19	Amylin Pharmaceuticals, Inc.	Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
ES2253353T3 (es)	2000-03-08	2006-06-01	Novo Nordisk A/S	Reduccion del colesterol serico.
CN103356996A (zh)	2000-05-19	2013-10-23	埃米林药品公司	Glp-1用于制备治疗急性冠脉综合征的药物的用途
EP1372660A2 (en)	2000-07-06	2004-01-02	Metabasis Therapeutics, Inc.	A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
US6420352B1 (en)	2000-07-19	2002-07-16	W. Roy Knowles	Hair loss prevention
EP2123293A3 (en) *	2000-12-14	2010-09-08	Amylin Pharmaceuticals, Inc.	Peptide YY and petide YY agonists for treatment of metabolic disorders
WO2002066479A1 (en)	2001-02-23	2002-08-29	Banyu Pharmaceutical Co.,Ltd.	Novel isoindole derivatives
WO2002067918A1 (en)	2001-02-27	2002-09-06	Banyu Pharmaceutical Co., Ltd.	Novel diallylmethylamine derivative

2003
- 2003-01-10 EP EP03700848A patent/EP1474163A2/en not_active Withdrawn
- 2003-01-10 CA CA002472882A patent/CA2472882A1/en not_active Abandoned
- 2003-01-10 JP JP2003557592A patent/JP4733922B2/ja not_active Expired - Fee Related
- 2003-01-10 WO PCT/GB2003/000062 patent/WO2003057235A2/en not_active Ceased
- 2003-01-10 AU AU2003201998A patent/AU2003201998C1/en not_active Ceased
- 2003-01-10 EP EP10186174.8A patent/EP2329839B1/en not_active Expired - Lifetime
2009
- 2009-07-23 AU AU2009203001A patent/AU2009203001B2/en not_active Ceased
- 2009-08-24 JP JP2009193064A patent/JP5226628B2/ja not_active Expired - Fee Related
2010
- 2010-12-10 JP JP2010275256A patent/JP2011052018A/ja active Pending

Publication	Publication Date	Title
JP2005519059A5 (2)	2006-03-02
JP2004501162A5 (2)	2008-07-24
DK1531791T3 (da)	2010-11-01	Forebyggelse og begrænsning af iskæmi
JP2005505579A5 (2)	2006-01-05
WO2006029393A8 (en)	2007-04-19	Process for preparation of mixtures of polypeptides using purified hydrobromic acid
JP2010529957A5 (2)	2011-07-07
EP2022505A3 (en)	2009-05-27	GLP-1, exendin-4, peptide analogs and uses thereof
EP1884247A3 (en)	2008-02-13	Gastrin compositions and formulations, and methods of use and preparation
DE60313858D1 (de)	2007-06-28	Peptidhaltige kosmetische oder pharmazeutische zusammensetzung
JP2004521123A5 (2)	2005-12-22
CO5640143A2 (es)	2006-05-31	Formulaciones parenterales de un peptido para el tratamiento de lupus eritematoso sistematico
JP2005516996A5 (2)	2006-03-30
WO2004009615A3 (en)	2004-08-05	Cd40-ligand lacking native-pattern glycosylation
ATE474589T1 (de)	2010-08-15	Angiogene peptide und ihre verwendungen
WO2003075944A3 (en)	2004-03-18	Interferon beta-like molecules for treatment of stroke
ATE291033T1 (de)	2005-04-15	Therapeutische peptide
WO2001042287A3 (en)	2002-02-14	Putative human g-protein coupled receptors
JP2006510360A5 (2)	2007-04-19
JP2005535281A5 (2)	2006-01-12
WO1998025955A3 (en)	1998-07-30	Cloned glucagon-like peptide-2 receptors
WO2002036633A3 (en)	2003-03-27	Human 7tm proteins and polynucleotides encoding the same
WO2002088183A3 (en)	2003-05-01	G-protein coupled receptor
WO2003033536A3 (en)	2003-07-03	G-protein coupled receptor
WO2001072842A3 (en)	2002-05-16	Human 7-transmembrane proteins and polynucleotides encoding the same
WO2002092624A3 (en)	2003-05-08	G-protein coupled receptor